TB Alternative Assets Ltd. has joined the biotech investing party by purchasing 3,158 shares of Regeneron Pharmaceuticals ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

Atwood & Palmer Inc. slightly reduced its stake in Regeneron Pharmaceuticals, selling 1,709 shares in Q1 while still holding ...

( NewsNation) — The interim CEO of 23andMe will face questions from lawmakers Wednesday about the DNA company’s data privacy amid a multistate lawsuit about its customers’ genetic data. The Senate ...

More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to ...

For more comprehensive information about current price movements while Regeneron shares crash, please visit CDS.

US biotech Regeneron and French drugmaker Sanofi are reviewing next steps for their experimental COPD therapy itepekimab ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

If you like what we do here, forward this email to a friend. They can get this newsletter every week through a STAT+ subscription, which is 50% off through next Monday.

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

Maine and 27 other states are suing 23andMe to stop the bankrupt DNA-test firm from selling customers’ genetic data.

US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 ...